Medivir - Science working wonders

From discovery to remedy

Medivir is a drug discovery and development company focusing on transformative cancer drugs. Our research and development are based on our extensive expertise in protease inhibitor design and nucleoside/nucleotide science.

For those most in need

Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.

Our projects >

Partnering for breadth and depth

Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects in various phases.

Partnership >

Portfolio highlights

MIV-711

Cathepsin K inhibitor (oral)

More about MIV-711

Remetinostat

HDAC inhibitor (topical)

More about Remetinostat
View all our current projects

News

2024/09/18

Medivir to present at the Pareto Securities Healthcare Conference

Read more
2024/09/16

Medivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO

Read more
2024/09/12

Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16

Read more
See all

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.

Read more